PATENT CLAIM ANALYSIS

Application Number: 15868469
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Claim (Index 9):
The method of  claim 3 , wherein the RAR\u03b1 antagonist is:

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15620411', '15868450', '15868459', '14507730', '15341969']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8329868237462789
- 35 USC 102 Novelty (BERT): 0.6562939785247065
- Combined Prediction Score: 0.8153175392241216
- Mean Citation Score: 481.98090600000006
- Max Citation Score: 611.9661
- Similarity Product: 555.7020184372724

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test